Diagnostics-Consultancy Center Mladost M Varna OOD — Clinical Trial Site

37 Registered trials

14 Currently recruiting

Organisation

Diagnostics-Consultancy Center Mladost M Varna OOD

Location

Varna, Bulgaria

Identifier

ORG-100043408

Address

Bulevard Republika 15, 9020, Bulgaria

Departments

-
Cabinet Ear, Nose and Throat
Cabinet No. 604 - Gastroenterology
Diagnostics-Consultancy Center Mladost M Varna OOD
N/A
NA
No department
Not applicable
Office of Psychiatry № 520
Office of Psychiatry №521
Psychiatric office
Psychiatric office №520
psychiatry
Unit V, office 520

Clinical trials at this site (37)

Search interface

A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavaila… Pending

2023-508981-13-00 Schizophrenia 2
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Pending

2025-522775-29-00 Depressive episodes associated with Bipolar disorder I 5
An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Depressive episodes associated with Bipolar disorder I 5
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521711-39-00 Lewy body Dementia psychosis (LBDP) 5 2026-05-17
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting

2023-503545-67-00 Tourette's Disorder 5 2024-04-30
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Lewy Body Dementia Psychosis (LBDP) 4 2025-12-04
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 Major Depressive Disorder 5 2025-10-22
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 Major Depressive Disorder 5 2025-10-22
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting

2023-503836-41-00 Major Depressive Disorder 5 2025-03-10
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Schizophrenia 4 2021-09-20
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended

2023-506867-33-01 Chronic Hepatitis B 4 2022-01-25
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB… Ended

2023-507376-50-00 Ulcerative Colitis 1 2024-09-27
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Cognitive disorder 4 2024-06-13